Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

Oncogene

Volumn 28, Issue 2, 2009, Pages 209-218

  Baba, T ^a,b   Convery, P A ^a   Matsumura, N ^a,b   Whitaker, R S ^a   Kondoh, E ^a,b   Perry, T ^a   Huang, Z ^a   Bentley, R C ^a   Mori, S ^c   Fujii, S ^b   Marks, J R ^a,c   Berchuck, A ^a,c   Murphy, S K ^a,c,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c DUKE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer initiating cell; CD133; DNA methylation; Ovarian cancer; Xenograft

Indexed keywords

CD133 ANTIGEN; CELL MARKER; DNA; DNA METHYLTRANSFERASE; HISTONE; HISTONE DEACETYLASE INHIBITOR; PLATINUM;

ANTIGEN DETECTION; ARTICLE; CARCINOGENESIS; CELL DIVISION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FLOW CYTOMETRY; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MODIFICATION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; ASCITIC FLUID; CARCINOMA; CELL DIVISION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HISTONES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PEPTIDES; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 58249095085     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.374     Document Type: Article

References (42)

1. Balch C, Nephew KP, Huang TH, Bapat SA. (2007). Epigenetic 'bivalently marked' process of cancer stem cell-driven tumorigenesis. Bioessays 29: 842-845.
2. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. (2005). Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029.
3. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C et al. (2007). NCBI GEO: mining tens of millions of expression profiles - database and tools update. Nucleic Acids Res 35: D760-D765.
4. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al. (2007). CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015.
5. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P et al. (2005). Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3696.
6. Chang JT, Nevins JR. (2006). GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22: 2926-2933.
7. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
8. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM et al. (2000). The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512-5520.
9. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A et al. (2007). Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 14: 14.
10. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M et al. (2005). ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65: 4320-4333.
11. Gan Q, Yoshida T, McDonald OG, Owens GK. (2007). Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells 25: 2-9.
12. Huang Z, Wen Y, Shandilya R, Marks JR, Berchuck A, Murphy SK. (2006). High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res 34: 555-563.
13. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC et al. (1994). Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74: 93-99.
14. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA et al. (1992). Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84: 1793-1798.
15. Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell 128: 683-692.
16. Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB et al. (2005). Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 8: 723-729.
17. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
18. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. (2006). Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67.
19. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N et al. (2007). Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 13: 78-83.
20. Lobo NA, Shimono Y, Qian D, Clarke MF. (2007). The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675-699.
21. Ma DQ, Cuccaro ML, Jaworski JM, Haynes CS, Stephan DA, Parod J et al. (2007a). Dissecting the locus heterogeneity of autism: significant linkage to chromosome 12q14. Mol Psychiatry 12: 376-384.
22. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO et al. (2007b). Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556.
23. Ma Y, Zou P, Xiao J, Huang S. (2002). The expression and functional characteristics of AC133 antigen in cord blood hematopoietic cells. Zhonghua Nei Ke Za Zhi 41: 798-800.
24. Maitland NJ, Collins AT. (2008). Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26: 2862-2870.
25. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S et al. (2007). Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161.
26. Mizrak D, Brittan M, Alison MR. (2008). CD133: molecule of the moment. J Pathol 214: 3-9.
27. Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC. (1992). Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52: 5119-5122.
28. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C et al. (2007). Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946.
29. O'Brien CA, Pollett A, Gallinger S, Dick JE. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
30. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L et al. (2007). A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
31. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H. (2007). Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6: 92-97.
32. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. (2007). Identification and expansion of human colon-cancer- initiating cells. Nature 445: 111-115.
33. Ruau D, Ensenat Waser R, Dinger TC, Vallabhapurapu DS, Rolletschek A, Hacker C et al. (2008). Pluripotency associated genes are reactivated by chromatin modifying agents in neurosphere cells. Stem Cells 31: 31.
34. Shiras A, Chettiar S, Shepal V, Rajendran G, Prasad R, Shastry P. (2007). Spontaneous transformation of human adult non-tumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells 25: 1478-1489.
35. Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK et al. (2004). Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103: 2055-2061.
36. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401.
37. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103: 11154-11159.
38. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C et al. (2007). Epigenetic stem cell signature in cancer. Nat Genet 39: 157-158.
39. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. (2008). Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10: R10.
40. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG et al. (1997). AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
41. Yin S, Li J, Hu C, Chen X, Yao M, Yan M et al. (2007). CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
42. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al. (2008). Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.